Agilent
Dako

PD-L1 IHC 28-8 pharmDx Interpretation Manual Non-Squamous Non-Small Cell Lung Cancer (nsNSCLC) % Tumor cell expression

IVD marked for in vitro diagnostic use (ROW Version)



Agilent
Trusted Answers

Table of Contents

Introduction

Intended use

For In Vitro Diagnostic Use

PD-L1 IHC 28-8 pharmDx is intended for use in specific types of cancer, which may vary by region. Please refer to the local Instructions for Use (IFU) for a description of the types of cancer in which PD-L1 IHC 28-8 pharmDx is intended for use.

PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) non-squamous non-small cell lung cancer (nsNSCLC) tissue using EnVision FLEX visualization system on Autostainer Link 48.

PD-L1 protein expression is defined as the percentage of evaluable tumor cells exhibiting partial or complete membrane staining at any intensity.

Note: Refer to local IFU for more information.

PD-L1 IHC 28-8 pharmDx Interpretation Manual - Overview

This PD-L1 IHC 28-8 pharmDx Interpretation Manual is provided as a tool to help guide pathologists and laboratory technicians to achieve correct and reproducible results in assessing PD-L1 expression in FFPE specimen. The goal of this manual is to familiarize you with the requirements for scoring non-squamous nsNSCLC specimens of previously treated patients stained with PD-L1 IHC 28-8 pharmDx. For the evaluation of non-squamous NSCLC specimens for patients seeking First-line Treatment, refer to the NSCLC Interpretation Manual. Pictomicrographs of example cases are provided for reference. The PD-L1 IHC 28-8 pharmDx package insert contains guidelines and technical tips for ensuring high-quality staining in your laboratory.

Review of this PD-L1 IHC 28-8 pharmDx Interpretation Manual will provide a solid foundation for evaluating slides stained with PD-L1 IHC 28-8 pharmDx. For more details, please refer to the current version of the package insert provided with PD-L1 IHC 28-8 pharmDx or visit www.agilent.com.

The included photomicrographs are nsNSCLC unless otherwise noted.

Acknowledgement

Pictomicrographs

Note: Pictomicrographs included in this interpretation manual include specimens provided by the following suppliers:

– Tissue samples supplied by BiolVT (Hicksville, NY, USA).

Assay Interpretation

The clinical interpretation of any staining, or the absence of staining, must be complemented by the evaluation of proper controls. An evaluation must be made by a qualified pathologist within the context of the patient's clinical history and other diagnostic tests. This product is intended for in vitro diagnostic (IVD) use.

Reporting results

To help understand what information should be reported to the treating physician, please refer to the Reporting Results section of this manual on page 25.

PD-L1 Overview

The PD-1/PD-L1 Pathway Controls the Immune Response in Normal Tissue

Programmed death-ligand 1 (PD-L1) is a transmembrane protein that binds to the programmed death-1 receptor (PD-1) during immune system modulation. The PD-1 receptor is typically expressed on cytotoxic T-cells and other immune cells, while the PD-L1 ligand is typically expressed on normal cells. Normal cells use the PD-1/PD-L1 interaction as a mechanism of protection against immune recognition by inhibiting the action of T-cells (Figure a). Inactivation of cytotoxic T-cells downregulates the immune response such that the inactive T-cell is exhausted, ceases to divide, and might eventually die by programmed cell death, or apoptosis.

The Tumor Escapes Detection by Utilizing the PD-1/PD-L1 Pathway

Many tumor cells are able to upregulate the expression of PD-L1 as a mechanism to evade the body's natural immune response. Activated T-cells recognize the PD-L1 marker on the tumor cell, similar to that of a normal cell, and PD-L1 signaling renders the T-cell inactive (Figure b). The tumor cell escapes the immune cycle, continues to avoid detection for elimination and is able to proliferate.

Anti-PD-1 Therapy Enables the Immune Response Against Tumors

Anti-PD-1 therapy works by blocking the PD-1/PD-L1 interaction between tumor cells and activated T-cells, helping to prevent immunosuppression, thereby enabling cytotoxic T-cells to actively remove tumor cells.

The Role of the PD-1/PD-L1 Pathway in Cancer

Limiting damage to healthy tissue

Inactivation of T-cells limits damage to healthy tissue.



The tumor escapes detection

Inactivation of T-cells reduces tumor cell killing.



Immuno-oncology therapies harness the immune response to fight tumors

Blocking PD-1/PD-L1 interaction enables cytotoxic T-cells to actively remove tumor cells.



PD-L1 IHC 28-8 pharmDx

Code SK005

PD-L1 IHC 28-8 pharmDx contains optimized reagents and protocol required to complete an IHC staining procedure of FFPE specimens using PT Link Pre-treatment Module and Autostainer Link 48.

Following incubation with the primary monoclonal antibody to PD-L1 or the Negative Control Reagent (NCR), specimens are incubated with a linker antibody specific to the host species of the primary antibody, and then are incubated with a ready-to-use visualization reagent consisting of secondary antibody molecules and horseradish peroxidase molecules coupled to a dextran polymer backbone (see Figure 1a). The enzymatic conversion of the subsequently added chromogen results in precipitation of a visible reaction product at the site of the antigen. The color of the chromogenic reaction is modified by a chromogen enhancement reagent (see Figure 1b). The specimen may then be counterstained and coverslipped. Results are interpreted using a light microscope. Control Slides containing two FFPE human cell lines are provided to validate staining runs.

PD-L1 IHC 28-8 pharmDx staining procedure



Figure 1a. PD-L1 IHC 28-8 pharmDx staining procedure.



Figure 1b. PD-L1 IHC 28-8 pharmDx staining procedure.

Figure 2. PD-L1 IHC 28-8 pharmDx, component.
All PD-L1 IHC 28-8 pharmDx reagents are to be used on the Autostainer Link 48. All reagents must be used as indicated in the IFU in order for the test to perform as specified.

PD-L1 IHC 28-8 pharmDx contains reagents to perform 50 tests in up to 15 individual runs (see Figure 2).

- EnVision FLEX Target Retrieval Solution, Low pH, 50x
- Peroxidase-Blocking Reagent
- Primary Antibody: Monoclonal Rabbit Anti-PD-L1, Clone 28-8
- Negative Control Reagent
- LINKER, Anti-Rabbit
- Visualization Reagent-HRP
- DAB+ Substrate Buffer
- DAB+ Chromogen
- DAB Enhancer
- PD-L1 IHC 28-8 pharmDx Control Slides

EnVision FLEX Wash Buffer (20x) (Code K8007) and EnVision FLEX Hematoxylin (Code K8008), are required but not included in the kit. Refer to the IFU for a complete list of required materials and equipment.

Technical Considerations for Optimal Performance of PD-L1 IHC 28-8 pharmDx

Optimal staining performance is achieved by adhering to the PD-L1 IHC 28-8 pharmDx protocol. Technical problems relating to the performance of PD-L1 IHC 28-8 pharmDx may arise in two areas; those involving specimen collection and specimen preparation prior to performing the test, as well as problems involving the actual performance of the test itself. Technical problems related to the performance of the test generally are related to procedural deviations and can be controlled and minimized through training and thorough understanding of the product instructions by the user.

Specimen Collection and Preparation

Specimens must be handled in a way which preserves the tissue for immunohistochemical staining. Tissue should be stained and interpreted as close to the time of biopsy as possible. The stability of PD-L1 immunoreactivity in tissue blocks has not been assessed. Tissue may be susceptible to loss of PD-L1 immunoreactivity with age. Confirm appropriate intact tumor morphology and the presence of sufficient tumor cells for evaluation. Use recommended methods of tissue processing for all specimens.

Tissue Processing

FFPE tissues are suitable for use. Specimens should be blocked into a thickness of 3 mm or 4 mm, fixed in 10% Neutral Buffered Formalin (NBF), and dehydrated and cleared in a series of alcohols and xylene, followed by infiltration with melted paraffin. The paraffin temperature should not exceed 60 °C. An ischemia time from excision to fixation start time of less than 30 minutes followed by immersion in NBF for 24–48 hours is recommended.

The use of PD-L1 IHC 28-8 pharmDx on decalcified tissue has not been validated and is not recommended.

Cut tissue specimens into sections of 4–5 µm. After sectioning, mount tissues on FLEX IHC microscope slides, Code K8020, or Superfrost Plus charged slides and place in a 58 ± 2 °C oven for 1 hour.

To preserve antigenicity, nsNSCLC tissue sections, once mounted on slides, should be stored in the dark at 2–8 °C, or room temperature up to 25 °C, and stained within 4 months of sectioning. Slide storage and handling conditions should not exceed 25 °C at any point post-mounting to ensure tissue integrity and antigenicity.

Control Tissues

Differences in processing and embedding in the user's laboratory may produce significant variability in results. Include positive and negative control tissue in each staining run, in addition to the PD-L1 IHC 28-8 pharmDx Control Slide.

Control tissue must represent one of the approved tumor indications for PD-L1 IHC 28-8 pharmDx as listed in the Intended Use of the IFU. Fix, process, and embed the control tissue in the same manner as patient specimens. Control tissue processed differently from the patient specimen validates reagent performance only and does not verify tissue preparation. The ideal positive control tissue gives weak to moderate positive staining. The variety of different cell types present in most tissue sections offers internal negative control sites; this should be verified by the user.

PD-L1 IHC 28-8 pharmDx Staining Procedure

The PD-L1 IHC 28-8 pharmDx reagents and instructions have been designed for optimal performance. Further dilution of the reagents, alteration of incubation times, temperatures, or instruments may give erroneous results.

Reagent Storage

Store all components of PD-L1 IHC 28-8 pharmDx, including Control Slides, in the dark at 2–8 °C when not in use on Autostainer Link 48. Do not use after the expiration date printed on the outside package.

Reagent Preparation

Equilibrate all components to room temperature (20–25 °C) prior to immunostaining.

EnVision FLEX Target Retrieval Solution, Low pH

Prepare a sufficient quantity of 1x EnVision FLEX Target Retrieval Solution, Low pH by diluting EnVision FLEX Target Retrieval Solution, Low pH (50x) 1:50 using distilled or deionized water; the pH of 1x EnVision FLEX Target Retrieval Solution must be 6.1 ± 0.2. Do not modify the pH of 1x EnVision FLEX Target Retrieval Solution after preparation under any circumstance. If a problem is suspected with the EnVision FLEX Target Retrieval Solution pH, please refer to the troubleshooting section for more information. One 30 mL bottle of EnVision FLEX Target Retrieval Solution, Low pH (50x), diluted 1:50 will provide 1.5 L of 1x reagent, sufficient to fill one PT Link tank, which will treat up to 24 slides per use. Discard 1x EnVision FLEX Target Retrieval Solution after three uses and do not use after 5 days following dilution. Note, the EnVision FLEX Target Retrieval Solution, Low pH (50x) is a red-colored solution.

Additional EnVision FLEX Target Retrieval Solution, Low pH (50x), if required, is available as Code K8005.

EnVision FLEX Wash Buffer (20x)

Prepare a sufficient quantity of EnVision FLEX Wash Buffer for the wash steps by diluting Wash Buffer (20x) 1:20 using distilled or deionized water and mix thoroughly. Store unused 1x solution at 2–8 °C for no more than one month. Discard buffer if cloudy in appearance. Refer to the User Guide for your Autostainer Link 48 for further information. EnVision FLEX Wash Buffer (20x) is available as Code K8007.

DAB+ Substrate-Chromogen Solution

Add 1 drop of DAB+ Chromogen per 1 mL of DAB+ Substrate Buffer and mix. Prepared DAB+ Substrate-Chromogen is stable for 5 days if stored in the dark at 2–8 °C. Mix the DAB+ Substrate-Chromogen Solution thoroughly prior to use. Any precipitate developing in the solution does not affect staining quality.

- If using an entire bottle of DAB+ Substrate Buffer, add 9 drops of DAB+ Chromogen. Although the DAB+ Substrate Buffer label states 7.2 mL, this is the usable volume and does not account for the "dead volume" of DAB+ Substrate Buffer in the bottle.
- The color of the DAB+ Chromogen may vary from clear to lavender-brown. This will not affect the performance of the product. Dilute as per the guidelines in this section. Adding excess DAB+ Chromogen to the DAB+ Substrate Buffer results in deterioration of the positive signal.

Control Slides

Each slide contains sections of two pelleted, FFPE cell lines: NCI-H226** with positive PD-L1 protein expression (originating from human lung squamous cell carcinoma with positive PD-L1 protein expression) and MCF-7 with negative PD-L1 protein expression (originating from human breast adenocarcinoma with negative PD-L1 protein expression).

*** Dr. AF Gazdar and Dr. JD Minna at NIH are acknowledged for their contribution in developing NCI-H226 (ATCC Number: CRL-5826™).*

Staining Protocol

Program slides by selecting PD-L1 IHC 28-8 pharmDx staining protocol from the options in the DakoLink drop-down menu. All of the required steps and incubation times for staining are preprogrammed in the DakoLink software. Print and attach slide labels to each slide.

Deparaffinization, Rehydration, and Target Retrieval

Use PT Link, Code PT100/PT101/PT200, to perform the Deparaffinization, Rehydration, and Target Retrieval 3-in-1 procedure.

- Set Pre-heat and Cool to 65 °C, and set Heat to 97 °C for 20 minutes.
- Fill PT Link tanks with 1.5 L per tank of EnVision FLEX Target Retrieval Solution, Low pH, 1x working solution to cover the tissue sections.
- Pre-heat the EnVision FLEX Target Retrieval Solution, Low pH to 65 °C.
- Immerse Autostainer racks containing mounted, FFPE tissue sections into the pre-heated EnVision FLEX Target Retrieval Solution, Low pH (1x working solution) in PT Link tank. Incubate for 20 minutes at 97 °C.
- As soon as Target Retrieval incubation has been completed and the temperature has cooled to 65 °C, remove each Autostainer slide rack with slides from the PT Link tank and **immediately** place the slides into a tank (e.g., PT Link Rinse Station, Code PT109) containing room temperature EnVision FLEX Wash Buffer working solution.
- Immerse Autostainer rack with slides in room temperature EnVision FLEX Wash Buffer for 5 minutes.

Staining and Counterstaining

- Place the Autostainer rack with slides on the Autostainer Link 48. Ensure slides remain wet with buffer while loading and prior to initiating the run. Dried tissue sections may display increased nonspecific staining.
- The instrument performs the staining and counterstaining procedures by applying the appropriate reagent, monitoring the incubation time, and rinsing slides between reagents. Counterstaining using EnVision FLEX Hematoxylin (Code K8008), for 7 minutes, is included in the staining protocol. Do not allow slides to dry prior to mounting.

Mounting

Use nonaqueous permanent mounting media. To minimize fading, store slides in the dark at room temperature (20–25 °C).

PD-L1 IHC 28-8 pharmDx Technical Checklist

Customer Name/Institution: _____

Name and Title: _____

Autostainer Link 48 Serial Number: _____ Software Version: _____

		Yes	No
1.	Regular preventive maintenance is performed on the Autostainer Link 48 and PT Link?	☐	☐
2.	PD-L1 IHC 28-8 pharmDx is used before the expiration date printed on the outside of the box?	☐	☐
3.	All PD-L1 IHC 28-8 pharmDx components, including Control Slides, are stored in the dark at 2–8 °C?	☐	☐
4.	All PD-L1 IHC 28-8 pharmDx components, including Control Slides, are equilibrated to room temperature (20–25 °C) prior to immunostaining?	☐	☐
5.	Appropriate positive and negative control tissue are identified?	☐	☐
6.	Tissues are fixed in neutral buffered formalin?	☐	☐
7.	Tissues are infiltrated with melted paraffin, at or below 60 °C?	☐	☐
8.	Tissue sections of 4–5 µm are mounted on FLEX IHC Microscope Slides, or Superfrost Plus charged slides?	☐	☐
9.	Specimens are stained within 4 months of sectioning when stored in the dark at 2-8 °C or at room temperature up to 25 °C?	☐	☐
10.	EnVision FLEX Target Retrieval Solution, Low pH is prepared properly?	☐	☐
11.	EnVision FLEX Wash Buffer is prepared properly?	☐	☐
12.	DAB+ Substrate-Chromogen Solution is prepared properly?	☐	☐
13.	The Deparaffinization, Rehydration, and Target Retrieval 3-in-1 procedure is followed, using PT Link?	☐	☐
14.	Slides remain wet with buffer while loading and prior to initiating run on Autostainer Link 48?	☐	☐
15.	The PD-L1 IHC 28-8 pharmDx protocol is selected on Autostainer Link 48?	☐	☐
16.	Slides are counterstained with EnVision FLEX Hematoxylin?	☐	☐
17.	Do you have all the necessary equipment to perform the PD-L1 IHC 28-8 pharmDx test according to the protocol? If not, specify what is missing in the comments below.	☐	☐

If you answered "No" to any of the above, consult with your local Agilent Technical Support Representative for assistance.

Additional Observations or Comments:

_____

_____

_____

Slide Evaluation Flowchart

The following flow of slide review is recommended when conducting interpretation of PD-L1 IHC 28-8 pharmDx. Refer to the detailed description on pages 15-20.



Figure 3. Slide evaluation procedure steps.

Recommendations for Interpretation of PD-L1 IHC 28-8 pharmDx

PD-L1 IHC 28-8 pharmDx evaluation must be performed by a pathologist using a bright field microscope. Before examining the patient specimen for PD-L1 staining, it is important to examine the hematoxylin and eosin (H&E) and controls first to assess staining quality. Examine a serial section of the patient specimen stained with H&E for histology and preservation quality.Then, examine the PD-L1 IHC 28-8 pharmDx Control Slide, the positive and negative control tissue slides, and the slide stained with the Negative Control Reagent for each patient case. Lastly, examine the patient specimen stained with Primary Antibody to assess staining of viable tumor cells.

Cytoplasmic staining, if present, is not considered positive for scoring purposes. Non-malignant cells and immune cells (e.g., such as infiltrating lymphocytes or macrophages) may also stain with PD-L1; however, these should not be included in the scoring for the determination of PD-L1 positivity.

Positive control tissue slides and negative control tissue slides should be supplied by the laboratory. Only the Control Slide is provided in the PD-L1 IHC 28-8 pharmDx kit.

PD-L1 staining is defined as complete circum ferential or partial linear plasma membrane staining at any intensity.

Patient Specimen Stained with H&E

An hematoxylin & eosin (H&E) stained section is required for the evaluation of histology and preservation quality.

PD-L1 IHC 28-8 pharmDx and the H&E staining should be performed on a serial section from the same paraffin block of the specimen.

PD-L1 IHC 28-8 pharmDx Control Slide

Examine the PD-L1 IHC 28-8 pharmDx Control Slide to ascertain that reagents are functioning properly. Each slide contains sections of cell pellets with positive and negative PD-L1 expression, see Figure 4. If any staining of the Control Slide is not satisfactory, all results with the patient specimens should be considered invalid. Do not use the Control Slide as an aid in the interpretation of patient results.



Assess the percentage of cells with plasma membrane staining and the staining intensity. Evaluate the overall staining intensity using the following guide:

0	No staining
1+	Weak staining
2+	Moderate staining
3+	Strong staining

Figure 4. Each Control Slide contains sections of cell pellets with positive and negative PD-L1 expression.

For the PD-L1 positive cell pellet, the following staining is acceptable, see Figure 5:

- Plasma membrane staining of ≥ 80% of cells.
- ≥2+ average staining intensity of cells with membrane staining.
- Non-specific staining < 1+ intensity.



Figure 5. Acceptable staining of positive Control.

For the PD-L1 negative cell pellet, the following staining is acceptable, see Figure 6:

- No specific staining.
- Non-specific staining < 1+ intensity.

Note: Staining of a few cells in the negative pellet on the Control Slide may occasionally be observed. The presence of ≤ 10 cells with distinct plasma membrane staining, and/or cytoplasmic staining with ≥ 1+ intensity within the boundaries of the negative cell pellet is acceptable.



Figure 6. Acceptable staining of negative Control.

Positive Control Tissue Slides

Examine the positive control tissue slides (Primary Antibody, NCR) to ascertain if tissues are correctly prepared, and reagents are functioning properly. Any nonspecific staining should be of ≤ 1+ staining intensity. Exclude necrotic or nonviable tumor cells from the evaluation. If the staining of positive control tissues is not satisfactory, all results with the patient specimens should be considered invalid. Do not use control tissue as an aid in the interpretation of patient results.

Negative Control Tissue Slides

Examine the negative control tissue slides (Primary Antibody, NCR) to confirm that there is no unintended staining. Any nonspecific staining should be ≤ 1+ staining intensity. If plasma membrane staining of malignant cells occurs in the negative control tissue, all results with the patient specimens should be considered invalid. Do not use control tissue as an aid in the interpretation of patient results.

Patient Specimen Stained with Negative Control Reagent

Examine the patient specimen stained with NCR to ascertain that reagents are functioning properly. The absence of plasma membrane staining of viable tumor cells is satisfactory and nonspecific staining should be ≤ 1+ staining intensity. If any staining is not satisfactory, results with the patient specimen should be considered invalid.

The NCR indicates nonspecific staining and allows better interpretation of the patient specimen stained with the Primary Antibody.



Figure 7. Absence of plasma membrane staining in nsNSCLC stained with Negative Control Reagent.

Patient Specimen Stained with Primary Antibody

Staining should be assessed within the context of any nonspecific staining of the patient specimen stained with NCR. A minimum of 100 viable tumor cells should be present in the PD-L1 stained patient slide in order to perform an evaluation.

1	At 4x objective magnification, carefully examine the tumor areas of the entire specimen. All areas with viable tumor cells on the specimen should be evaluated. Exclude nonmalignant cells, necrotic cells, and cellular debris. Cytoplasmic staining, if present, should be disregarded.
2	Use the 10–20x objective magnifications to determine the percentage of viable tumor cells expressing PD-L1 membranous staining. The 40x objective can be used for confirmation if needed. Tumor cells are considered to be PD-L1 positive if they exhibit either partial linear or complete circumferential staining of the plasma membrane at any intensity. Nonmalignant cells and immune cells (e.g., infiltrating lymphocytes or macrophages) may also stain with PD-L1 but must be excluded.
3	Record if the specimen has PD-L1 % tumor cell expression < 1% or ≥ 1%. When determining the percentage of stained tumor cells in the entire specimen, the numerator is the number of stained viable tumor cells and the denominator is the total number of viable tumor cells in the specimen.

$$\% \text{ PD-L1 expression} = \frac{\text{\# PD-L1 staining tumor cells}}{\text{Total \# viable tumor cells}} \times 100$$



Figure 8. Red arrows show partial linear plasma membrane staining of viable tumor cells.



Figure 9. Red arrows show complete circumferential plasma membrane staining of viable tumor cells.



Figure 10. Red arrows show cytoplasmic staining as observed throughout the specimen. Exclude cytoplasmic staining from scoring.



Figure 11. Red arrows show viable tumor cells. Green arrows show staining of immune cells. Exclude immune cells from scoring.

Tips and Special Considerations

- Include the entire specimen for evaluation of PD-L1 % tumor cell expression
- Use higher magnifications to confirm cell types and areas absent of staining
- Be careful not to overlook weak 1+ staining, which can be missed at 4x and 10x
- Disregard cytoplasmic staining
- Necrotic tissue may stain but should be excluded
- Exclude any nonmalignant cells and immune cells
- Granular staining must demonstrate a perceptible and convincing membrane pattern

Non-evaluable Specimen

The specimen should be considered non-evaluable if there are fewer than 100 viable tumor cells. A different section from the same block or another block from the same patient may be required to present a sufficient quantity of viable tumor cells for PD-L1 IHC 28-8 pharmDx evaluation.

Indeterminate Specimen

The recognition of tumor cell membrane staining has been hampered for reasons attributed to the biology of the tumor tissue sample rather than improper sample preparation. For example, high cytoplasmic staining of the tumor cells can hamper scoring of the membrane staining. An additional cut section or section from another block of the same patient may be required for PD-L1 IHC 28-8 pharmDx evaluation.

PD-L1 IHC 28-8 pharmDx Suggested Scoring Methods for Calculating PD-L1 Percent Tumor Cell Expression

Agilent offers two different examples of scoring techniques that may be used when assessing stained specimens exhibiting different staining patterns.

Example 1: Calculating PD-L1 % tumor cell expression in a specimen with a small PD-L1 staining tumor area

At lower objective magnification, assess the entire specimen for the presence of PD-L1 staining in viable tumor cells at any intensity. Any nonmalignant and immune cells staining PD-L1 positive must be excluded.

- In this example, assume the number of tumor cells is equally distributed in the tumor and that there are a total of 1,000 viable tumor cells in the entire specimen.
- 10% of the tumor area has staining, 90% of the tumor area has no staining.

At a higher objective magnification, carefully examine PD-L1 staining tumor area (blue circle in Figure 12). PD-L1 positive staining is defined as complete circumferential and/or partial linear plasma membrane staining of tumor cells at any intensity.

- 50 out of 100 viable tumor cells are staining PD-L1 positive in the single region of the tumor area (blue circle in Figure 8).
- 50 out of 1000 viable tumor cells are staining PD-L1 positive in the entire tumor specimen (Method 1) which may also be described as 50% PD-L1 positive in a single region representing 10% of the tumor area (Method 2).



Figure 12. Example of a tumor with a small PD-L1 staining area.

Determine the overall percentage of PD-L1 staining tumor cells for the entire specimen as shown:

Method 1

$$\frac{\text{50 tumor cells staining PD-L1 positive}}{\text{1,000 viable tumor cells}} \times 100 = \text{5\% tumor cell expression}$$

Method 2

$$\frac{50\% \times 10\%}{100} = \text{5\% tumor cell expression}$$

Example 2: Calculating PD-L1 % tumor cell expression in a specimen with heterogeneous staining

At lower objective magnification, assess the entire specimen for the presence of PD-L1 staining in viable tumor cells at any intensity. Visually divide the tumor area into regions. Any nonmalignant and immune cells staining PD-L1 positive must be excluded.

- The tumor area is divided into four equivalent quadrants in Figure 9.

At a higher objective magnification, assess and calculate the percentage of PD-L1 staining tumor cells in each quadrant. PD-L1 positive staining is defined as complete circumferential and/or partial linear plasma membrane staining of tumor cells at any intensity.

- The percentage of PD-L1 staining tumor cells for each of the four respective quadrants are 80%, 30%, 50% and 100%.



Figure 13. Example with heterogenous PD-L1 staining area.

Determine the overall percentage of PD-L1 staining tumor cells for the entire specimen:

$$\frac{(80\% + 30\% + 50\% + 100\%)}{4 \text{ quadrants}} = 65\% \text{ tumor cell expression}$$

Reporting Results

Suggested information to include when reporting results with PD-L1 IHC 28-8 pharmDx in nsNSCLC

PD-L1 IHC 28-8 pharmDx, Code SK005

Summary of Sample Tested:

Date of Run: _____ PD-L1 IHC 28-8 pharmDx Lot: _____

Staining Run Log ID: _____ Specimen ID: _____

Patient Identifier: _____

Type of Service: IHC Stain with Manual Interpretation _____

Other: _____

Type of Tissue: _____

Additional Tests Performed with PD-L1 IHC 28-8 pharmDx: _____

PD-L1 IHC 28-8 pharmDx Controls Results:

PD-L1 IHC 28-8 Control Slide:	Pass ☐	Fail ☐
Positive Control Tissue Slides:	Pass ☐	Fail ☐
Negative Control Tissue Slides:	Pass ☐	Fail ☐
Patient Specimen, Negative Control Reagent:	Pass ☐	Fail ☐

PD-L1 Results: Viable Tumor Cells Present: ☐ ≥ 100 cells ☐ Not evaluable

☐ PD-L1 expression is ≥ 1%	☐ PD-L1 expression is < 1%
☐ PD-L1 expression is ≥ 5%	☐ PD-L1 expression is < 5%
☐ PD-L1 expression is ≥ 10%	☐ PD-L1 expression is < 10%

Other Comments to Treating Physician: _____

Note: *PD-L1 IHC 28-8 pharmDx was validated for invasive nsNSCLC tissue samples and not for lesions with foci of dysplasia or carcinoma in situ. An H&E stained slide should accompany each PD-L1 stained sample to allow a proper assessment of invasive carcinoma, carcinoma in situ, and adjacent normal epithelium.*

Guidelines for Scoring PD-L1 IHC 28-8 pharmDx

Agilent emphasizes that scoring of PD-L1 IHC 28-8 pharmDx must be performed in accordance with the guidelines established in the package insert and within the context of best practices and the pathologist's experience.

The percentage of viable tumor cells exhibiting positive membrane PD-L1 staining at any intensity in the entire specimen determines the PD-L1 IHC 28-8 pharmDx result. Scoring guidelines and reporting recommendations are presented in Table 1.

Staining Pattern	Examples of non-squamous NSCLC	Examples of result reporting
< 1% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.		PD-L1 expression < 1%
≥ 1% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.		PD-L1 expression ≥ 1%
≥ 5% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.		PD-L1 expression ≥ 5%
≥ 10% of the viable tumor cells exhibit complete circumferential or partial linear plasma membrane staining at any intensity.		PD-L1 expression ≥ 10%

Table 1. Guidelines for scoring and reporting of PD-L1 IHC 28-8 pharmDx

Examples of PD-L1 IHC 28-8 pharmDx Immunostaining



Figure 14. PD-L1 expression < 1%. 20x objective magnification.



Figure 15. PD-L1 expression < 1%. 20x objective magnification.



Figure 16. PD-L1 expression < 1%. 20x objective magnification.



Figure 17. PD-L1 expression ≥ 1%. 20x objective magnification.



Figure 18. PD-L1 expression ≥ 1%. 20x objective magnification.



Figure 19. PD-L1 expression ≥ 1%. 20x objective magnification.



Figure 20. PD-L1 expression ≥ 5%. 20x objective magnification.



Figure 21. PD-L1 expression ≥ 5%. 20x objective magnification.



Figure 22. PD-L1 expression ≥ 5%. 20x objective magnification.

Artifacts

Nonspecific Staining

Nonspecific staining is defined as staining that is not related to primary antibody-antigen interaction and represents issues such as reagent trapping, cartilage staining, DAB deposits, tissue folds, and edge drying. Other notable factors include, but are not limited to, pre-analytic fixation and processing of the specimen, incomplete removal of paraffin from sections, and incomplete rinsing of slides.

The use of fixatives other than 10% neutral buffered formalin may be a source of nonspecific staining. If nonspecific staining interferes with interpretation of specific staining, the slide may be considered unacceptable.

Possible cause of nonspecific staining

- Improper drying of slides; ensure slides remain wet with buffer while loading onto Autostainer Link 48 and prior to initiating run
- Improper deparaffinization procedure
- Incomplete rinsing of reagents from slides
- Improper mixing of wash buffer

The nonspecific staining present on the patient specimen stained with Negative Control Reagent is useful in determining the level of nonspecific staining in the same patient tissue specimen stained with PD-L1. All specimens must have ≤ 1+ nonspecific staining.

Immune cells

Intense staining of inflammatory cell infiltrate in the tumor may occur. Inflammatory cells are not included in determining the % tumor cell expression.

Necrosis

Necrotic tissue may show nonspecific staining and should not be included in scoring % tumor cell expression.



Figure 23. PD-L1 expression ≥ 10%. 20x objective magnification.



Figure 24. PD-L1 expression ≥ 10%. 20x objective magnification.



Figure 25. PD-L1 expression ≥ 10%. 20x objective magnification.

Troubleshooting Guide for PD-L1 IHC 28-8 pharmDx

Problem	Probable Cause	Suggested Action
1. No staining of control or specimen slides	1a. Programming error	1a. Verify that the SK005 PD-L1 IHC 28-8 pharmDx program was selected for programming of slides
	1b. Lack of reaction with DAB+ Substrate - Chromogen Solution (DAB)	1b. Verify that DAB+ Substrate-Chromogen Solution was prepared properly
	1c. Sodium azide in wash buffer	1c. Use only EnVision FLEX Wash Buffer, Code K8007
	1d. Degradation of Control Slide	1d. Check kit expiration date and kit storage conditions on outside of package
2. Weak staining of specimen slides	2a. Inappropriate fixation method used	2a. Ensure that only neutral buffered formalin fixative and approved fixation methods are used
	2b. Insufficient reagent volume applied	2b. Check size of tissue section and reagent volume applied
	2c. Inappropriate wash buffer used	2c. Use only EnVision FLEX Wash Buffer, Code K8007
3. Weak staining of specimen slides or the positive cell line on the Agilent-supplied Control Slide	3a. Inadequate target retrieval	3a. Verify that the 3-in-1 pre-treatment procedure was correctly performed
	3b. Inappropriate wash buffer used	3b. Use only EnVision FLEX Wash Buffer, Code K8007
4. Excessive nonspecific staining of slides	4a. Paraffin incompletely removed	4a. Verify that the 3-in-1 pre-treatment procedure was correctly performed
	4b. Slides dried while loading onto the Autostainer Link 48	4b. Ensure slides remain wet with buffer while loading and prior to initiating run
	4c. Nonspecific binding of reagents to tissue section	4c. Check for proper fixation of the specimen and/or the presence of necrosis
	4d. Inappropriate fixation method used	4d. Ensure that only neutral buffered formalin fixative and approved fixation methods are used
	4e. Inadequate mixing of wash buffer	4e. Ensure wash buffer is properly mixed
5. Tissue detached from slides	5a. Use of incorrect microscope slides	5a. Use FLEX IHC Microscope Slides (Code K8020), or Superfrost Plus slides
	5b. Inadequate preparation of specimens	5b. Cut sections should be placed in a 58 ± 2 °C oven for 1 hour prior to staining
6. Excessively strong specific staining	6a. Inappropriate fixation method used	6a. Ensure that only approved fixatives and fixation methods are used
	6b. Inappropriate wash buffer used	6b. Use only EnVision FLEX Wash Buffer, Code K8007
7. 1x EnVision FLEX Target Retrieval Solution is cloudy in appearance when heated	7. When heated the 1x EnVision FLEX Target Retrieval Solution turns cloudy in appearance	7. This is normal and does not influence staining

Problem	Probable Cause	Suggested Action
8. 1x EnVision FLEX Target Retrieval Solution does not meet pH specifications	8a. pH meter is not calibrated correctly	8a. Ensure pH meter is calibrated per manufacturer's recommendations. After re-calibration, re-test the pH of 1x EnVision FLEX Target Retrieval Solution. Do not modify the pH of 1x EnVision FLEX Target Retrieval Solution. If the pH is outside the acceptable range (6.1 ± 0.2), discard 1x EnVision FLEX Target Retrieval Solution. Prepare new 1x EnVision FLEX Target Retrieval Solution. Check the pH of the new 1x EnVision FLEX Target Retrieval Solution
	8b. Inferior quality water is used to dilute the EnVision FLEX Target Retrieval Solution concentrate	8b. Ensure that distilled or deionized water is used to prepare 1x Target Retrieval Solution
	8c. Incorrect Target Retrieval Solution is used	8c. Ensure that the correct EnVision Flex Target Retrieval Solution specified in “Materials Provided” and “Reagent Preparation” sections of the IFU is used

Note: *If the problem cannot be attributed to any of the above causes, or if the suggested corrective action fails to resolve the problem, please contact Agilent Pathology Support for further assistance. Additional information on staining techniques and specimen preparation can be found in the Education Guide: Immunohistochemical Staining Methods (Taylor C. R. and Rudbeck L. Education Guide: Immunohistochemical Staining Methods – Sixth Edition. Dako, Carpinteria, California. 2013; available from Agilent).*

Bibliography

- Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline – Fourth Edition. CLSI document M29-A4 (ISBN 1-56238-962-9). CLSI, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA; Vol.34 No.8; **2014**.

- Clinical and Laboratory Standards Institute (CLSI). Quality assurance for Design Control and Implementation of Immunohistochemistry Assays; Approved guideline – Second Edition. CLSI document I/LA28-A2 (ISBN1-56238-745-6). CLSI, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA; Vol.31 No.4; **2011**.

- Department of Health, Education and Welfare, National Institutes for Occupational Safety and Health, Rockville, MD. Procedures for the decontamination of plumbing systems containing copper and/or leadazides. DHHS (NIOSH) Publ. No. 78-127. **1976**.

- Omata M. D., C-T Liew., et al. Nonimmunologic Binding of Horseradish Peroxidase to Hepatitis B Surface Antigen: A Possible Source of Error in Immunohistochemistry. *Am. J. Clin. Pathol*. **1980**, 73(5), 626-632.

- PD-L1 IHC 28-8 pharmDx Instructions for Use

- Phelps R. M., Johnson B. E., et al. NCI-navy medical oncology branch cell line database. *J. Cell. Biochem*.**1996**, 63(S24), 32-91.

- Therese Phillips M. A., Pauline Simmons B. S., et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for Non-Small Cell Lung Cancer. *Appl. Immunohistochem. Mol. Morphol*. **2015**, 23(8), 541-549.

- Taylor C. R. and Rudbeck L. Education Guide: Immunohistochemical Staining Methods – Sixth Edition. Dako, Carpinteria, California; **2013**.

- Topalian S. L., Drake C. G., Pardoll D. M. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. *Curr. Opin. Immunol.* **2012**, 24(2), 207-212.

- Topalian S. L., Hodi F. S., et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *N. Engl. J. Med*. **2012**, 366, 2455-2465.

- Wang C., Kent B. T., et al. *In Vitro* Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and *In Vivo* Toxicology in Non-Human Primates. *Cancer Immunol. Res*. **2014**, 2(9), 846-856.

Learn more:

www.agilent.com/en/product/pharmdx/pd-l1-ihc-28-8-pharmdx

For countries outside of the United States, see the local OPDIVO and YERVOY product labels for approved indications and expression cutoff values to guide therapy.

D75759

Published in the USA, May 9, 2023
29126EN-ROW 2023MAY09

Agilent

Trusted Answers